Monday, January 24, 2022 4:25:17 AM
They're biologics. There is no formula the way there would be for a small molecule. You'd have a salt form of a small molecule to bring it in and out of solution more easily so you could purify it. Salt in a biologic would be part of a buffer to keep it suspended and from degraded to quickly. It wouldn't have a salt added to it the way a chemist would do for a small molecule.
The mRNA vaccines don't have antigen exposure the way a classic vaccine does. They use the body the same way a virus does to create the antigen within the body so antibodies can be raised.
I believe attenuated viruses are less common for classic vaccine and instead the antigen is genetically inserted into a vector/plasmid, copies are churned out in large flasks and the antigen bearing vector is purified and added to a buffer solution (which would include salts) and put in vials for distribution.
The salt you put on your salad is NaCl. Na is positively charged. Cl is negatively charged. The easily pair up and separate in solution. Anything with a Cl on it that can do that is a salt. Anything in the same column as Na can do that because of the number of free electrons and the ease and stability of pairing. The reaction gets more volatile as you go down the list. Those are your big boom molecules when exposed to water quickly and in large quantity.
The mRNA vaccines don't have antigen exposure the way a classic vaccine does. They use the body the same way a virus does to create the antigen within the body so antibodies can be raised.
I believe attenuated viruses are less common for classic vaccine and instead the antigen is genetically inserted into a vector/plasmid, copies are churned out in large flasks and the antigen bearing vector is purified and added to a buffer solution (which would include salts) and put in vials for distribution.
The salt you put on your salad is NaCl. Na is positively charged. Cl is negatively charged. The easily pair up and separate in solution. Anything with a Cl on it that can do that is a salt. Anything in the same column as Na can do that because of the number of free electrons and the ease and stability of pairing. The reaction gets more volatile as you go down the list. Those are your big boom molecules when exposed to water quickly and in large quantity.
Recent CYDY News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
